 |
|
|
| |
MK-8591/Islatravir vs ART Resistance / Metabolics
|
| |
| |
Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection.....http://www.natap.org/2019/IAS/IAS_15.htm
Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP....http://www.natap.org/2019/IAS/IAS_67.htm
MK-8591 Potency and PK Provide High
Inhibitory Quotients at Low Doses QD and QW
http://www.natap.org/2019/CROI/croi_46.htm
Common NRTI mutations, including M184I/V, thymidine analog mutations, K65R, and K70E, confer low fold-shifts in antiviral potency, and MK-8591 retains greater IQs against these NRTI-resistant viruses than those of TDF, TAF, and 3TC with WT virus.
|
| |
|
|
|
|
|
